Cases & Deals

NGM Biopharmaceuticals completes $107 million IPO

Clients NGM Biopharmaceuticals, Inc.

Jones Day served as IP counsel in connection with the $107 million initial public offering of NGM Biopharmaceuticals, Inc. (NASDAQ: NGM). NGM is a clinical stage biopharmaceutical company focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases.